6-K filed Aug 17, 2026 at 08:54 ET
Argenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune myositis. The study met its primary endpoint (p=0.0011) in the combined IMNM and DM population, showing a 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo. This is the first Phase 3 study to show statistically significant results in IMNM, a subtype with no approved therapy, and represents a major pipeline expansion into rheumatology for argenx, opening a new addressable market of approximately 60,000 patients in the US alone.